PALO ALTO, Calif., Nov. 17, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, announced that new Phase 3 ATTRibute-CM analyses and real-world evidence for acoramidis in transthyretin amyloid cardiomyopathy (ATTR-CM) were presented at the American Heart Association (AHA) Scientific Sessions 2026 in Chicago, Illinois, and the XX International Symposium on Amyloidosis (ISA) 2026 in Montevideo, Uruguay. At AHA 2026, BridgeBio had 2 moderated posters and 3 posters, and at ISA 2026, BridgeBio had 28 total abstracts accepted comprising 12 new poster presentations and 16 encore poster presentations. Acoramidis is the only selective small molecule, orally administered, near-complete (≥90%) transthyretin (TTR) stabilizer.
At AHA 2026, a new ATTRibute-CM analysis presented by Mazen Hanna, M.D. of Cleveland Clinic, U.S. showed that acoramidis reduced heart failure (HF) events quickly and across the board. Key findings included:
“ATTR-CM causes heart failure in our patients when misfolded transthyretin proteins build up as amyloid fibrils in the heart muscle, making the walls stiff and rigid. It is the cause of urgent doctor visits, hospital stays, and, ultimately, death, so preventing these events matters most to people with ATTR-CM, their families and their care teams,” said Dr. Hanna. “In this analysis, acoramidis reduced the risk of a first heart failure event by 45%, with separation from placebo within the first month and lower rates of every type of heart failure event we looked at, from outpatient diuretic intensification through hospitalization and heart failure death. Seeing an effect that early, and across a broad range of patients, is meaningful for a disease where time matters. This is strong validation that early treatment with acoramidis can improve clinical outcomes.”
At ISA 2026, the Bayer-led mODIficATTR study extended real-world evidence favoring acoramidis over tafamidis into Europe. Bayer is BridgeBio’s exclusive European licensing partner for acoramidis. The study was presented by Roman Pfister, M.D. of University Hospital Cologne, DE. Using German longitudinal prescription claims covering approximately 64 million people, it followed 488 treatment-naive individuals starting acoramidis and 659 starting tafamidis from April 2025 through April 2026. Key findings included:
Six analyses of ATTRibute-CM presented at ISA 2026 indicated that the early eGFR dip with acoramidis associated with potentially rapid kidney-protective activity was (i) a consistent pharmacodynamic response that is observed irrespective of baseline AF status, diabetes status, RAAS inhibitor use, and genotype with favorable clinical outcomes observed through Month 12 and Month 30 across all of these subgroups, (ii) not accompanied by clinically meaningful changes in laboratory measures such as electrolytes, hemoglobin, hematocrit, or blood pressure, and (iii) did not lead to clinically meaningful changes in markers of kidney safety in participants with CKD stage 4, whose kidney function remained stable over 30 months. Detailed findings in the analyses included:
New U.S. real-world data presented at ISA 2026 showed that TTR stabilizers remain the predominant first-line therapy of choice for ATTR-CM, even after the introduction of the first TTR silencer. Treatment Patterns in Newly Diagnosed Patients with Transthyretin Amyloid Cardiomyopathy in the United States: Results from a Real-World Study Show Transthyretin Stabilizers Are the Predominant First-Line Treatment, presented by Liana Hennum, M.P.T., M.H.A. of BridgeBio, U.S., used Komodo Healthcare Map U.S. claims data to identify 349 adults with ATTR-CM who newly started acoramidis, tafamidis, or vutrisiran between March and June 2025, immediately after FDA approval of the first TTR silencer for ATTR-CM. The results showed:
Additionally, ten more analyses were shared across AHA 2026 and ISA 2026, including one independently led by Abbott, which included:
BridgeBio also shared 16 encore posters at ISA 2026, further supporting acoramidis’ early heart failure effect and benefits compared to tafamidis in the real-world. Encores also suggested acoramidis benefits to the kidney, biomarkers, cardiac structure, in variant ATTR-CM, and in female patients.
Acoramidis is approved as Attruby® by the U.S. FDA and the Singapore Health Sciences Authority (HSA) and is approved as BEYONTTRA® by the European Medicines Agency (EMA), Japanese Pharmaceuticals and Medical Devices Agency, Swissmedic, the Swiss Agency for Therapeutic Products, the UK Medicines and Healthcare Products Regulatory Agency, the Brazilian Health Regulatory Agency (ANVISA) and the Australian Therapeutic Goods Administration (TGA) with all labels specifying near-complete stabilization of TTR.
Additional data on the benefit of Attruby for individuals with ATTR-CM is planned for future medical meetings.
About Attruby® (acoramidis)
INDICATION
Attruby is a transthyretin stabilizer indicated for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular death and cardiovascular-related hospitalization.
IMPORTANT SAFETY INFORMATION
Adverse Reactions
Diarrhea (11.6% vs 7.6%) and upper abdominal pain (5.5% vs 1.4%) were reported in patients treated with Attruby versus placebo, respectively. The majority of these adverse reactions were mild and resolved without drug discontinuation. Discontinuation rates due to adverse events were similar between patients treated with Attruby versus placebo (9.3% and 8.5%, respectively).
About BridgeBio
BridgeBio exists to develop transformative medicines for genetic conditions. Millions of people worldwide living with genetic conditions lack treatment options, often because drug development for small patient populations can be commercially challenging. We aim to bridge the gap between advancements in genetic science and meaningful medicines for underserved patient populations. Our decentralized, hub-and-spoke model is designed for speed, precision, and scalability. Autonomous and empowered teams focus on individual conditions, while a central hub provides the clinical, regulatory, and commercial capabilities needed to bring innovation to market. For more information, visit bridgebio.com and follow us on LinkedIn, X, Facebook, Instagram, YouTube, and TikTok.
BridgeBio Forward-Looking Statements
This press release contains forward-looking statements. Statements in this press release may include statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended (the Securities Act), and Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act), which are usually identified by the use of words such as “anticipates,” “believes,” “continues,” “estimates,” “expects,” “hopes,” “intends,” “may,” “plans,” “projects,” “remains,” “seeks,” “should,” “will,” and variations of such words or similar expressions, or the negative of these terms or other comparable terminology are intended to identify forward-looking statements, though not all forward-looking statements necessarily contain these identifying words. BridgeBio intends these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act. These forward-looking statements include statements regarding the potential clinical significance and therapeutic implications of the real-world and ATTRibute-CM data regarding acoramidis, including the potential speed, breadth, durability and broader clinical significance of observed benefits associated with acoramidis, including with respect to heart failure events, cardiovascular hospitalizations, mortality and other clinical outcomes; the potential clinical and therapeutic implications of analyses regarding the early eGFR dip observed following initiation of acoramidis, including the potential for such changes to reflect kidney-protective or other cardiorenal activity and the potential relationships among such changes, kidney function and clinical outcomes; the potential comparative clinical significance of real-world and other analyses evaluating acoramidis and tafamidis, including the potential for acoramidis to provide greater clinical stability; the potential for artificial intelligence and other screening models described in this press release to improve or accelerate identification of individuals with ATTR-CM, including the potential utility of sex-specific screening approaches and planned external validation; and BridgeBio’s plans and expectations regarding additional analyses, future research, publications and presentations of data regarding acoramidis. Although the Company believes that its plans, intentions, expectations and strategies as reflected in or suggested by those forward-looking statements are reasonable, the Company can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a number of risks, uncertainties and assumptions, including, but not limited to, the risk that results from retrospective, observational, real-world evidence studies, including studies based on electronic health records or administrative claims data, may be subject to confounding, selection bias, residual bias, incomplete or inaccurate data, limited follow-up or other limitations and may not be predictive of future clinical outcomes or treatment effects; that results from post hoc analyses, subgroup analyses, exploratory analyses, indirect comparisons or other analyses may not be predictive of future clinical outcomes or treatment effects and may not be replicated in additional analyses or studies; that observed effects on heart failure events, cardiovascular hospitalizations, mortality or other clinical outcomes may not be replicated, persist over longer periods or translate into meaningful long-term clinical benefit; that observed associations between an early eGFR dip and favorable clinical outcomes may not be replicated or establish kidney-protective or other cardiorenal activity, and mechanistic or prognostic interpretations of such data may not be borne out by further analyses or additional data; that observed associations and differences between acoramidis and tafamidis may not be replicated in additional analyses, independent studies or longer-term data, may not establish a causal treatment difference or greater clinical stability, or may not translate into improved long-term clinical outcomes; that artificial intelligence or other screening models may not be validated, may not identify individuals with ATTR-CM with sufficient accuracy or utility, or may not meaningfully improve or accelerate diagnosis, and planned external validation may be delayed, modified or may not confirm prior findings; that additional analyses or future research may yield results that differ from or do not confirm the findings described in this press release; that plans or timing for future analyses, medical meeting presentations or scientific publications may change; the impacts of current macroeconomic and geopolitical events, including changing conditions from hostilities in Ukraine and the Middle East, increasing rates of inflation and changing interest rates, on business operations and expectations, as well as those risks set forth in the Risk Factors section of the Company’s most recent Quarterly Report on Form 10-Q and Annual Report on Form 10-K and the Company’s other filings with the U.S. Securities and Exchange Commission. Moreover, the Company operates in a very competitive and rapidly changing environment in which new risks emerge from time to time. These forward-looking statements are based upon the current expectations and beliefs of the Company’s management as of the date of this press release, and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as required by applicable law, BridgeBio assumes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
BridgeBio Media Contact:
Kaitlyn Reilly, Director, Communications
contact@bridgebio.com
(650) 789-8220
BridgeBio Investor Contact:
BridgeBio Investor Relations
ir@bridgebio.com

| Nov-17 | |
| Nov-12 | |
| Nov-11 | |
| Nov-09 | |
| Nov-06 | |
| Nov-03 | |
| Oct-29 | |
| Oct-29 | |
| Oct-29 | |
| Oct-22 | |
| Oct-22 | |
| Oct-16 | |
| Oct-12 | |
| Oct-11 | |
| Oct-11 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, alerts, and much more.
Learn more about Finviz Elite